Table 2 Savings if the treatment had been carried out in the 2 years of the study
From: Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases
1631 BEVACIZUMAB VIAL SHARING | COST DIFFERENCE | ||
|---|---|---|---|
1631 Bevacizumab PMVG | BRL$2,106,991.04 USD$543,808.02 | BRL$33,109.30 USD$8545.43 | BRL$2,073,881.74 USD$535,264.35 |
1631 Ranibizumab PMVG | BRL$3,550,230.32 USD$916,295.80 | BRL$33,109.30 USD$8545.43 | BRL$3,517,121,02 USD$907,761.26 |
1631 Aflibercept PMVG | BRL$4,848,685.73 USD$1,251,433.68 | BRL$33,109.30 USD$8545.43 | BRL$4,815,576.43 USD$1,242,889.77 |